$DVAX current price just an appetizer. Risk has be
Post# of 88924
The independent Data and Safety Monitoring Board (DSMB) recommended twice to go ahead with ongoing phase 3 study of HEPLISAV-B(TM). Source: Press release.
This will drive prices much higher! Short term (30-45 days), we may see hitting $30. Watch what happens as each passing month goes buy with no new information from Dynavax. The lack of information is a huge positive as it means that the trial is progressing along just fine as far as safety is concerned.
Phase 3 to release October, 2015
GLTA